Trial · NCT04180462
Increasing Optimal Use of HPV Vaccination in Primary Care
NCT04180462, Not applicable, Completed, Washington University School of Medicine; results first posted 2024-02-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Increasing Optimal Use of HPV Vaccination in Primary Care. Trials, record NCT04180462. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04180462
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Increasing Optimal Use of HPV Vaccination in Primary Care
- NCT number
- NCT04180462
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 20 participants, actual
- Lead sponsor
- Washington University School of Medicine
- Conditions
- Human Papillomavirus Vaccines
- Interventions
- Practice Facilitation, Education, Audit and Feedback, Communication Strategy
- First posted
- 2019-11-27
- Last updated
- 2025-03-25
- Results first posted
- 2024-02-20
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Initiation of the HPV Vaccine 2-dose Series. | 24 months | The proportion of eligible preteens who initiate the HPV vaccine before their 13th birthday, at 24 months, post randomization |
| Primary | Completion of the HPV Vaccine 2-dose Series. | 24 months | The proportion of eligible preteens who complete the HPV vaccine before their 13th birthday, at 24 months, post randomization. |
| Secondary | Sustainability of the Intervention Benefit for Initiation of the HPV Vaccine. | 36 months | The proportion of eligible preteens who receive the 1st dose of HPV vaccine before their 13th birthday at 36 months, post randomization |
| Secondary | Sustainability of the Intervention Benefit for Completion of the HPV Vaccine. | 36 months | The proportion of eligible preteens who complete the HPV vaccine before their 13th birthday, at 36 months, post randomization |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Initiation of the HPV Vaccine 2-dose Series. | 24 months | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Completion of the HPV Vaccine 2-dose Series. | 24 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Sustainability of the Intervention Benefit for Initiation of the HPV Vaccine. | 36 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Sustainability of the Intervention Benefit for Completion of the HPV Vaccine. | 36 months | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Initiation of the HPV Vaccine 2-dose Series. | Intervention Group | 1723 | Participants | ||
| Initiation of the HPV Vaccine 2-dose Series. | Wait List Control Group | 1219 | Participants | ||
| Completion of the HPV Vaccine 2-dose Series. | Intervention Group | 1135 | Participants | ||
| Completion of the HPV Vaccine 2-dose Series. | Wait List Control Group | 809 | Participants | ||
| Sustainability of the Intervention Benefit for Initiation of the HPV Vaccine. | Intervention Group | 1812 | Participants | ||
| Sustainability of the Intervention Benefit for Initiation of the HPV Vaccine. | Wait List Control Group | 1052 | Participants | ||
| Sustainability of the Intervention Benefit for Completion of the HPV Vaccine. | Intervention Group | 1279 | Participants | ||
| Sustainability of the Intervention Benefit for Completion of the HPV Vaccine. | Wait List Control Group | 703 | Participants |
Source ClinicalTrials.gov
Participant flow10
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Intervention Group | 4,362 | 10 |
| Overall Study | STARTED | Wait List Control Group | 3,025 | 10 |
| Overall Study | 24 Months Post-randomization | Intervention Group | 2,151 | 10 |
| Overall Study | 24 Months Post-randomization | Wait List Control Group | 1,615 | 10 |
| Overall Study | 36 Months Post-randomization | Intervention Group | 2,211 | 10 |
| Overall Study | 36 Months Post-randomization | Wait List Control Group | 1,410 | 9 |
| Overall Study | COMPLETED | Intervention Group | 4,362 | 10 |
| Overall Study | COMPLETED | Wait List Control Group | 3,025 | 9 |
| Overall Study | NOT COMPLETED | Intervention Group | 0 | 0 |
| Overall Study | NOT COMPLETED | Wait List Control Group | 0 | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Intervention Group (24 Months Post-randomization) | 0 | 2,151 |
| Total, all-cause mortality | Wait List Control Group (24 Months Post-randomization) | 0 | 1,615 |
| Total, all-cause mortality | Intervention Group (36 Month Post-randomization) | 0 | 2,211 |
| Total, all-cause mortality | Wait List Control Group (36 Months Post-randomization) | 0 | 1,410 |
| Total, other adverse events | Intervention Group (24 Months Post-randomization) | 0 | 2,151 |
| Total, other adverse events | Wait List Control Group (24 Months Post-randomization) | 0 | 1,615 |
| Total, other adverse events | Intervention Group (36 Month Post-randomization) | 0 | 2,211 |
| Total, other adverse events | Wait List Control Group (36 Months Post-randomization) | 0 | 1,410 |
| Total, serious adverse events | Intervention Group (24 Months Post-randomization) | 0 | 2,151 |
| Total, serious adverse events | Wait List Control Group (24 Months Post-randomization) | 0 | 1,615 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers2
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01CA235615 | RCT to Evaluate an Implementation Strategy to Increase Optimal Use of HPV Vaccine in Primary Care | KING, ALLISON A | WASHINGTON UNIVERSITY | NATIONAL CANCER INSTITUTE | 2019 to 2024 |
Source NIH RePORTER
Trial comparisons4
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Intervention Group vs Wait List Control Group: Initiation of the HPV Vaccine 2-dose Series. | Trial comparisons |
| Intervention Group vs Wait List Control Group: Sustainability of the Intervention Benefit for Completion of the HPV Vaccine. | Trial comparisons |
| Intervention Group vs Wait List Control Group: Completion of the HPV Vaccine 2-dose Series. | Trial comparisons |
| Intervention Group vs Wait List Control Group: Sustainability of the Intervention Benefit for Initiation of the HPV Vaccine. | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04180462
GET https://conductscience.org/api/trials/v1/NCT04180462/registered